Neoadjuvant Her2-targeted Therapy and Immunotherapy With Pembrolizumab
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: HER2-positive Breast Cancer|Breast Cancer
Interventions: DRUG: Paclitaxel|DRUG: Trastuzumab|DRUG: Pertuzumab|DRUG: Pembrolizumab
Sponsor: University of Texas Southwestern Medical Center
Collaborators: Merck Sharp & Dohme LLC|Breast Cancer Research Foundation